EMA revises guidelines for first-in-human studies


To facilitate matters for actors and reduce the risks for participants in clinical studies, the European Medicines Agency (EMA) has revised its guidelines for first-in-human studies.

Through the revision of the “Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products”, the existing EU guidelines for early clinical trials have now been extended. The aim of the revision is to facilitate the transfer between the pre-clinical and clinical phases. The document deals with issues such as quality aspects, study design, dose calculation and implementation.

The revision comes into force on 1 February 2018.

Read about the revisionexternal link on EMA’s website.

Source: ema.europa.eu


Office for Clinical Studies

Östra Hamngatan 26
SE-411 09 Göteborg


Phone: +46 (0)31 757 41 75

E-mail: kliniskastudier@vr.se


Would you like to subscribe to news, good examples or calendar events from clinicalstudies.se?

Clinical Studies Sweden - a collaboration between The Swedish Research Council and the Swedish Association of Local Authorities and Regions.